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Objectives: To demonstrate the health economic impact of OM-85, a bacterial 
lysates based immunostimulant, for its approved indications in China. MethOds: 
A cost effectiveness decision tree model was constructed. The model compared 
OM-85 with the best supportive care therapy for the treatment of chronic bronchi-
tis and rhinosinusitis in Chinese population. Clinical efficacy and adverse events 
(AE) data were included in the model based on a thorough literature review. All 
localized direct treatment costs, including drug cost, AE costs, and medical treat-
ment costs for underlining diseases were included from Chinese payer perspective 
for both OM-85 and best supportive care group. A Key Opinion Leaders (KOL) survey 
was conducted to validate the local treatment costs. A total of 20 senior physi-
cians specialized in respiratory, ENT, allergy, and immunology fields were selected 
from tertiary hospitals in Beijing, Shanghai, Guangzhou, Hangzhou, Chongqiong, 
Chengdu and Wuhan to form an representative geographic sample. All physicians 
were requested to complete a questionnaire which included the clinical manage-
ment of acute exacerbation of chronic bronchitis and rhinosinusitis in China, the 
management of OM-85 related AEs, and the attitude towards the clinical efficacy 
and effects of OM-85. Incremental cost effectiveness ratio (ICER) was calculated 
based on the above efficacy and cost information. Results: The results indicate 
that, when compared with best supportive care therapy,OM-85 is a dominant 
therapy (with better clinical efficacy and lower overall costs) in Chinese popula-
tion for the clinical management of chronic bronchitis and rhinosinusitis One 
way sensitivity analyses were performed and the ICER result was demonstrated 
to be robust. cOnclusiOns: Based on its clinical efficacy in preventing acute 
exacerbations of chronic bronchitis and rhinosinusitis, OM-85, when compared 
with standard care therapy, proved to be a dominant therapy (better clinical effi-
cacy and lower overall costs) in Chinese population for the clinical management 
of chronic bronchitis and rhinosinusitis.
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Objectives: Unmotivated smokers are a unique population and have rarely 
been specifically targeted for recruitment into smoking cessation trials. While 
accurate cost data are essential to estimate resource utilization in replicating 
an intervention, currently the costs of recruiting unmotivated smokers are not 
reported in the literature. We aim to describe the costs and recruitment meth-
ods associated with successful enrollment of smokers who are unmotivated to 
quit. MethOds: Economic analysis was conducted on data from KC-Quest trial, 
an NIH funded large RCT comparing the efficacy of Motivational Interviewing 
(MI), matched intensity health education (HE), and brief advice (BA) for prompting 
quit attempts and cessation among smokers low in motivation to quit smoking. 
In this study retrospective analysis of cost data was performed to identify direct 
and activity-based time costs incurred for recruitment purposes. Costs were ana-
lyzed from the perspective of a researcher that seeks to replicate this recruitment 
protocol. To determine the most cost effective option to recruit patients for the 
trial one-way sensitivity analysis using a tornado diagram was conducted. All 
costs are reported in 2012 dollar values. Results: A total of 774 persons were 
screened for participation, and 255 were ultimately enrolled in the study. Overall 
cost of recruitment totaled $16,931.94 (direct costs= $12,252.50; activity-based 
time costs= $4,679.43), translating to $21.88 per recruitment contact and $66.40 
per successfully enrolled participant. The most successful recruitment methods 
were newspaper advertisements and word-of-mouth. Financial incentives also 
motivated many to participate. cOnclusiOns: We are the first to report the cost 
of recruiting smokers with low motivation to quit and shed light on this unique 
challenge. Study results may inform decision-makers, researchers, and clinicians 
seeking to enroll for unmotivated smokers. This economic analysis can serve as a 
guide to determine the budget for actively enrolling these patients in future trials 
and suggests the most efficient means to do so.
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Objectives: The purpose of this study is to assess health status of Korean adults 
with COPD using EQ5D and the association between health status and disease 
severity using spirometry as a lung function measure. MethOds: A stratified 
multistage clustered probability design was used to select a nationally repre-
sentative sample. From the Fourth and Fifth Korea National Health and Nutrition 
Examination Survey, 20,261 adults over the age of 40 years were selected. These 
subjects completed the utility measure, EQ-5D-3L and were separated into four 
severity groups according to FEV1 percent of predicted normal using the GOLD 
clinical guideline. Population sampling weights were applied to adjust for the 
over-sampling of the minority groups. Regression analysis was conducted using 
EQ-5D as the dependent variable to estimate the association between COPD and 
EQ-5D index score with SAS Ver. 9.3 program. Results: Among 20,261 adults, 
2,087 COPD patients were selected based on GOLD criteria (a ratio of FEV1 to 
FVC of less than 0.7). The mean utility of COPD patients was 0.906(SE 0.004) com-
pared to 0.922(SE 0.001) in the non-COPD control group. Utility was significantly 
reduced due to COPD(p= 0.0001). Within each GOLD stage, the variation (SE) was 
Objectives: Bacterial lysates reduce acute exacerbations for patients with 
chronic obstructive pulmonary disease. The purpose of this study was to conduct 
a cost-benefit analysis of bacterial lysates from a payer perspective through the 
results from a Meta analysis and a Delphi panel survey in China. MethOds: A 
cost-benefit analysis was to project the 12-month health benefits and costs asso-
ciated with immunostimulation treatments. Acute exacerbations were served as 
a measure of effectiveness. Treatment effectiveness data were derived from the 
meta-analysis. Costs were obtained from a Delphi panel survey of treating acute 
exacerbation for chronic obstructive pulmonary disease in China. One-way sensi-
tivity analysis was used to explore each parameter’s impacts on the uncertainty 
of the results. Results: The group receiving routine care only was dominated by 
the group with bacterial lysates plus routine care. Sensitivity analysis proved the 
robustness of the results. For a COPD patient, compared to the routine care as 
control group, the alternative treatment with bacterial lysates could reduce 1.9 
exacerbations in 12 months (WMD, -1.865; 95% CI, -2.128 to -1.603; P< 0.00001). The 
projected 12-month cost savings of a patient receiving bacterial lysates plus routine 
care was CNY14476. The cost of patients receiving bacterial lysates plus routine care 
was significantly lower than those receiving routione care only. cOnclusiOns: 
For patients with COPD, treatments with bacterial lysates can improve patient out-
comes and reduce costs.
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Objectives: To assess, from a societal perspective, the cost-effectiveness of 100% 
whey-based partially hydrolyzed infant formula (pHF-W) compared to standard 
cow’s milk formula (CMF) as an early, short-term nutritional intervention to pre-
vent atopic dermatitis (AD) in high-risk Singaporean infants. MethOds: A Markov 
model was developed to simulate, from birth through age 6, the incidence of AD 
and its ensuing burden in cohorts of high-risk infants fed with pHF-W or CMF 
during for the first 4 months of life. Epidemiologic and clinical data were from 
the German Infant Nutritional Intervention (GINI) trial. AD treatment patterns and 
outcomes were based on expert opinion. Key modeled outcomes included reduc-
tion in AD risk, time spent after an AD diagnosis, days with AD symptoms, quality-
adjusted life years (QALYs), and direct/indirect costs (in 2013 Singapore $). A 3% 
annual discount rate was used. Multivariate probabilistic sensitivity analysis was 
used to generate 95% probabilistic confidence intervals (CI) around the modeled 
outcomes. Results: Feeding high-risk infants pHF-W instead of CMF resulted in 
reductions of (i) 14-percentage points (95% CI: 3%, 24%) in the 6-year risk of AD, (ii) 
8.25 months (95% CI: 5.00, 11.61) in the time spent post-AD diagnosis, and (ii) 14.6 
days (95% CI: 8.9, 20.3) with AD symptoms; and in an increase of 0.022 QALYs (95% 
CI: 0.008, 0.074). Estimated AD-related discounted cost (all per child) when feeding 
high-risk infants with pHF-W vs. CMF were $1,316 (95% CI: $858, $2028) and $2,055 
(95% CI: $1,443, $2,820), respectively, for a net difference favoring pHF-W of $739 
(95% CI: $1,138, $326). The mean overall and annualized (undiscounted) cost of AD 
per child developing AD was $5,814 and $1,392, respectively. cOnclusiOns: This 
mathematical model suggests that the burden of AD in childhood is high and that 
feeding high-risk infants with pHF-W instead of CMF should reduce this burden.
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Objectives: To systematically review the economic evaluations of the Xiyanping 
injection to treat respiratory diseases. MethOds: Database as PubMed, ISI Web of 
knowledge, The Cochrane Library, CBM, WanFang Data, CNKI and VIP were electroni-
cally searched from inception to February 28st, 2014. Two reviewers independently 
screened studies according to inclusion and exclusion criteria and extracted data. 
Then, descriptive analysis was performed for included studies. A 10-item quality 
checklist modified was used to appraise the quality of studies. Results: 6 economic 
evaluations and cost studies were included of which 4 studies’ quality were low, 1 
was high and 1 was medium. All studies adequately documented effectiveness of 
interventions. However, the costs of interventions were not well reported in 2 studies. 
2 studies inadequately conducted sensitivity analysis and discounting. The disease of 
6 studies includingbronchitis(2studies), upper respiratory tract infection, herpangina, 
hand-foot-and-mouth disease and viral pneumonia. The studies result showed that 
cost-effectiveness of Xiyanping injection is poor than Tanreqing injection and have 
more adverse reaction in 2 studies and It is poor than Yanhuning injection, but less 
adverse reaction in 2 studies. Xiyanping injection is better than anti-viral medicine 
in 2 studies. 1study indicated that Xiyanping is more cost-effectiveness by atom-
ized than intravenous drip. cOnclusiOns: Xiyanping injection is not better than 
other proprietary Chinese medicine for the treatment of respiratory diseases in cost-
effectiveness analysis, however it is better than anti-viral medicine, and less adverse 
reaction. The quality of included studies is weaken the conclusion. There remains a 
strong need to improve the quality of reporting.
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